GlassScriptPhysician profile
Sarah Dynes
NPI 1730668161
$2,329.31
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $51.04 · 2022: $792 · 2023: $1,228 · 2024: $259.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,486.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,486.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $305.18 | 2022-2024 | Farxiga, Airsupra, Breztri |
| Novartis Pharmaceuticals Corporation | $267.23 | 2022-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $227.12 | 2022-2024 | |
| Astellas Pharma US INC | $168.48 | 2022-2024 | Veozah |
| Pfizer INC. | $166.62 | 2022-2023 | |
| Novo Nordisk INC | $136.72 | 2022-2024 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $135.41 | 2022-2024 | Prolia, Evenity |
| Ironshore Pharmaceuticals INC. | $133.90 | 2022-2023 | Jornay Pm |
| Otsuka America Pharmaceutical, INC. | $120.32 | 2023-2024 | Rexulti |
| Abbvie INC. | $95.09 | 2021-2023 | |
| Lundbeck LLC | $86.99 | 2022-2023 | Rexulti |
| Lilly USA, LLC | $64.28 | 2022-2023 | Mounjaro |
| E.R. Squibb & Sons, L.L.C. | $61.27 | 2022-2024 | Eliquis |
| Dexcom, INC. | $52.05 | 2023 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $49.80 | 2023 | Cologuard Collection Kit |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $45.51 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.02 | 2022 | |
| Insulet Corporation | $34.75 | 2023-2024 | Omnipod |
| Amarin Pharma, INC. | $22.21 | 2022 | |
| Organon LLC | $20.97 | 2022 | |
| Supernus Pharmaceuticals, INC. | $16.10 | 2023 | Qelbree |
| Exeltis, USA INC. | $15.61 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.45 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.43 | 2021 | |
| Sanofi-Aventis U.S. LLC | $13.54 | 2023 | |
| Evofem Biosciences, INC. | $11.62 | 2021 | |
| Inogen, INC. | $3.64 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Dynes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.